According to experts at Statens Serum Institut (SSI), the antigen-tests are far less sensitive than the PCR-test. These antigen-tests can only be utilised as an addendum to the normal PCR-tests. Furthermore, it is only the positive test results that can be utilised in the further management of COVID-19 infections.
Click here to read more on this matter (in Danish).
PentaBase is acting in the fight against COVID-19 infections and makes it easier, more affordable, and quicker for both companies and private people to get tested.
Since the pandemic, we at PentaBase have done everything in our power to help Denmark and its citizens. Currently, Denmark, among many other countries, is experiencing a major increase in the number of COVID-19 cases. Today, we are the largest partner for Danish businesses where we ensure workstream can be kept running, despite the challenges of the virus.
Now, the national test facilities experience great stress that demonstrates longer wait time for bookings and response time for test results. This stress demands higher capacity of tests in Denmark.
– We have established a large test capacity, normally exclusively offered to our business customers, but now offered to everyone in need of a quick COVID-19 test – CEO of PentaBase, Ulf Bech Christensen, explains.
At PentaBase, we have chosen to meet the high demand for fast COVID-19 PCR tests by establishing test facilities and laboratories in several parts of the country and increasing the test capacity in Denmark. We have previously focused on stopping infection chains by offering our COVID-19 test service to businesses. However, today, we have chosen to make our tests more accessible to private citizens.
– Due to this, we have lowered our prices from Wednesday, October 28 significantly to make our services available for both private people and businesses. This applies to all our facilities in Denmark – Ulf Bech adds.
All bookings made after October 28 will have the difference from the new prices refunded.
Click here to book a quick test at one of our four facilities.
Sunday night, the final data was ready.
PentaBase is proud to present that we have completed the internal validation of our first COVID-19 product. By a great effort from the PentaBase employees, we have developed and validated our own test for diagnostics of COVID-19. Since we started, our approach has been to incorporate our own sensitive DNA-technology for improved diagnostics of Coronavirus – and we believe that we have succeeded in this. We haven’t just developed a highly sensitive test, but we have also combined three analyses in a single tube with great success. It is fantastic to be able to reduce the consumption of limiting resources, in a time where less patients are tested due to the lack of reagents (see Figure 1).
During the last week, PentaBase has been in close dialogue with collaborators regarding the expansion of the Danish test capacity. Together, we are now planning and designing an approach, which can contribute to an expansion of the tests capacity in the Danish health care system. We are currently testing and comparing PentaBases RNA-purification in the current workflow, which is used in the healthcare system.
From the beginning, our main focus in this crisis has been to increase the number of Danes that can be screened for Coronavirus in order to contain the spread and minimize the impact on human lives and society. We hope that our technology can contribute to this.
For more information:
PentaBase has been named profile of the month by BioPeople – Denmark’s Life Science Cluster
Read the article here: Working to support Denmark combating the COVID-19 disease
Photo: Morten Albek
Our CEO highlights the fact that PentaBase is providing tools to fight against SARS-CoV-2:
”We have communicated broadly about our ability to help out detect COVID 19, because we have technologies and a knowledge that may support healthcare workers, scientists and patients combating the COVID-19 disease: SARS-CoV-2 oligonucleotides, SARS-CoV-2 test assay and instruments for SARS-CoV-2 detection,” Ulf B. Christensen says.
A devoted team of experts is behind PentaBase’s efforts to develop these necessary products:
“At PentaBase every single worker is highly specialised and trained in developing the assays for cancer diagnostics. The company divides the team into different specialised units, each of them experts in their area.”
As our board is international, PentaBase has canceled all physical board meetings until SARS-CoV-2 is under control and the restrictions on traveling across borders will no longer be into force. Furthermore, our weekly scientific and medical discussions with our chairman of the board are temporarily suspended. He is, of course, still paid by PentaBase and chairman of the board with the responsibilities that follow.
We are proud that he has signed up to help the Danish healthcare system as a volunteer in the fight against Coronavirus. He is a medical doctor of training.
Let’s all do our best to limit the impact of the virus outbreak. Stay healthy.